Observed medical and surgical complications of prolonged barbiturate coma for refractory status epilepticus.
BACKGROUND
Refractory status epilepticus is often treated with third-line therapy, such as pentobarbital coma. However, its use is limited by side effects. Recognizing and preventing major and minor adverse effects of prolonged pentobarbital coma may increase good outcomes. This study retrospectively reviewed direct and indirect medical and surgical pentobarbital coma.


METHODS
Retrospective chart review of all patients with refractory status epilepticus treated with pentobarbital over a 1 year period at a large tertiary care center. We collected baseline data, EEG data, and complications that were observed.


RESULTS
Overall, nine patients [median age 46.4 (IQR 21.7, 75.5) years] were induced with pentobarbital coma median 11 (IQR 3, 33) days after seizure onset for a median of 9 (IQR 3.5, 45.4) days. A total of four to eight concurrent antiepileptics were tried prior to the pentobarbital coma. Phenobarbital, due to recurrence of seizures on weaning pentobarbital coma, was required in seven patients. Observed complications included peripheral neuropathy (77.8%), cerebral atrophy (33.3%), volume overload (44.4%), renal/metabolic (77.8%), gastrointestinal (66.6%), endocrine (55.6%), cardiac/hemodynamic/vascular (77.8%), respiratory (100%), and infectious (77.8%). The number of complications trended with duration of induced coma but was nonsignificant. Median ICU length of stay was 40 (IQR 28, 97.5) days. Overall, five patients were able to follow commands after a median 37 (IQR 25.5, 90) days from coma onset. There were eight patients that were discharged from hospital with three remaining in a prolonged unresponsive state. There was one patient that died prior to discharge.


CONCLUSIONS
This study highlights the high morbidity in patients with refractory status epilepticus requiring pentobarbital coma. Anticipating and addressing the indirect and direct complications in prolonged pentobarbital coma may improve survival and functional outcomes in patients with refractory status epilepticus.
University of Missouri, Department of Neurology, 5 Hospital Drive, CE 540, Columbia, MO 65211, USA.
Christopher R
CR
Newey
Cleveland Clinic, Department of Neurology, Cleveland, OH, USA.
Dolora
D
Wisco
University of Missouri, Department of Neurology, Columbia, MO, USA.
Premkumar
P
Nattanmai
Wake Forest University School of Medicine, Neurology and Critical Care, Winston Salem, NC, USA.
Aarti
A
Sarwal
cerebral atrophy; pentobarbital coma; refractory status epilepticus
Acta Anaesthesiol Scand. 1992 May;36(4):369-77
1595344
Epilepsia. 2010 Feb;51(2):251-6
19817823
Ann Pharmacother. 2008 Oct;42(10):1502-6
18698010
Neurology. 1987 Mar;37(3):500-3
3822147
Neurol Res. 2007 Oct;29(7):667-71
18173905
Anaesthesist. 1987 Jul;36(7):356-61
2889393
Neurocrit Care. 2008;9(1):122-4
18270846
Epilepsia. 1990 Jan-Feb;31(1):61-7
2303014
Med Hypotheses. 2007;69(6):1179-82
17555884
Neurology. 1988 Mar;38(3):395-400
3279338
Intensive Care Med. 2007 Nov;33(11):1876-91
17639340
Ther Drug Monit. 1987 Sep;9(3):255-8
3672566
Acta Anaesthesiol Scand. 1989 Feb;33(2):122-8
2922981
Neurology. 1999 Mar 10;52(4):746-9
10078721
Epilepsia. 2011 Oct;52 Suppl 8:39-41
21967359
N Engl J Med. 1998 Apr 2;338(14):970-6
9521986
Neurology. 2001 Sep 25;57(6):1036-42
11571331
Nat Clin Pract Nephrol. 2007 Sep;3(9):515-20
17717564
Neurocrit Care. 2005;2(3):330-41
16159085
Acta Neurochir (Wien). 1992;117(3-4):153-9
1414516
Crit Care Med. 2010 Dec;38(12):2295-303
20890201
Epilepsia. 2006;47 Suppl 1:41-5
17044825
Lancet Neurol. 2011 Oct;10(10):922-30
21939901
Neurology. 1993 May;43(5):895-900
8492944
Crit Care. 2008;12(6):238
19040777
Neurocrit Care. 2009;10(1):73-5
18338269
Eur J Clin Pharmacol. 1998 Sep;54(7):529-34
9832294
Neurocrit Care. 2008;9(2):189-97
18415032
J Neurosurg. 1982 Feb;56(2):254-9
7054434
Crit Care. 2014 May 21;18(3):R103
24886712
Neurology. 1996 Jul;47(1):83-9
8710130
Epilepsia. 1989 Jul-Aug;30(4):464-71
2752997
Epilepsia. 2002 Feb;43(2):146-53
11903460